Advertisement
Screener

Viridian Therapeutics, Inc./DE (VRDN) Payments of Debt Issuance Costs

2.0 / 5 stars · 36/91 Roast Me

Viridian Therapeutics, Inc./DE Payments of Debt Issuance Costs

Viridian Therapeutics, Inc./DE (VRDN) reported Payments of Debt Issuance Costs of $7.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Financing Activities

us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-08-06

  • Viridian Therapeutics, Inc./DE payments of debt issuance costs for fiscal 2025 was $478.00K.
  • Viridian Therapeutics, Inc./DE payments of debt issuance costs for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
  • Viridian Therapeutics, Inc./DE payments of debt issuance costs for fiscal 2023 was $514.00K, a 15.25% increase from fiscal 2022.
  • Viridian Therapeutics, Inc./DE payments of debt issuance costs for fiscal 2022 was $446.00K.
Period endPayments of Debt Issuance Costs 6 monthPayments of Debt Issuance Costs 12 monthPayments of Debt Issuance Costs 12 month as first filed
2026-06-30$7.51M
10-Q · filed 2026-08-06
2025-12-31$478.00K
10-K · filed 2026-02-26
2025-06-30$0.00
10-Q · filed 2026-08-06
2024-12-31$0.00
10-K · filed 2026-02-26
2023-12-31$514.00K
10-K · filed 2026-02-26
$0.00
10-K · filed 2024-02-27
2022-12-31$446.00K
10-K · filed 2025-03-03
2021-12-31$0.00
10-K · filed 2024-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
uniQure N.V. (QURE)$2.416B-4.93
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
Zai Lab Ltd (ZLAB)$2.241B-113.34
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03